These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30410040)

  • 21. Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil.
    da Silva CM; de Peder LD; Guelere AM; Horvath JD; Silva ES; Teixeira JJV; Bertolini DA
    PLoS One; 2018; 13(9):e0203272. PubMed ID: 30192795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients.
    Mitsumoto F; Murata M; Ura K; Takayama K; Hiramine S; Shimizu M; Toyoda K; Ogawa E; Furusyo N; Hayashi J
    J Infect Chemother; 2015 Apr; 21(4):264-71. PubMed ID: 25596071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role?
    Mohr R; Schierwagen R; Schwarze-Zander C; Boesecke C; Wasmuth JC; Trebicka J; Rockstroh JK
    Medicine (Baltimore); 2015 Dec; 94(50):e2127. PubMed ID: 26683921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B virus genotype G: prevalence and impact in patients co-infected with human immunodeficiency virus.
    Dao DY; Balko J; Attar N; Neak E; Yuan HJ; Lee WM; Jain MK
    J Med Virol; 2011 Sep; 83(9):1551-8. PubMed ID: 21739445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
    Coffin CS; Osiowy C; Myers RP; Gill MJ
    J Clin Virol; 2013 Jun; 57(2):103-8. PubMed ID: 23465393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B viral replication markers and hepatic fibrosis in untreated chronic hepatitis B virus infection with and without HIV coinfection in Zambia.
    Muula GK; Bosomprah S; Sinkala E; Nsokolo B; Musonda T; Hamusonde K; Bhattacharya D; Lauer G; Chung RT; Mulenga LB; Wandeler G; Vinikoor MJ
    AIDS; 2023 Nov; 37(13):2015-2020. PubMed ID: 37467044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis B Virus-Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort.
    Dezanet LNC; Kassime R; Miailhes P; Lascoux-Combe C; Chas J; Maylin S; Gabassi A; Rougier H; Delaugerre C; Lacombe K; Boyd A
    Clin Infect Dis; 2022 Mar; 74(6):1012-1021. PubMed ID: 34197574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
    Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
    Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda.
    Mutwa PR; Boer KR; Rusine JB; Muganga N; Tuyishimire D; Reiss P; Lange JM; Geelen SP
    Pediatr Infect Dis J; 2013 Mar; 32(3):246-51. PubMed ID: 22976050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana.
    Chadwick D; Ankcorn M; Sarfo F; Phillips R; Fox Z; Garcia A; Appiah L; Bedu-Addo G; Geretti AM
    J Antimicrob Chemother; 2012 Dec; 67(12):2939-42. PubMed ID: 22915461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
    Archampong TN; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Gillani FS; Yang H; Boamah I; Flanigan T; Kwara A
    BMC Infect Dis; 2016 Jan; 16():14. PubMed ID: 26759172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine.
    Kooij KW; Wit FW; van Zoest RA; Schouten J; Kootstra NA; van Vugt M; Prins M; Reiss P; van der Valk M;
    AIDS; 2016 Jul; 30(11):1771-80. PubMed ID: 27088320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
    Matthews GV; Cooper DA; Dore GJ
    Antivir Ther; 2007; 12(1):119-22. PubMed ID: 17503756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of hepatitis B virus infection on HIV response to antiretroviral therapy in a Chinese antiretroviral therapy center.
    Yang R; Gui X; Xiong Y; Gao SC; Yan Y
    Int J Infect Dis; 2014 Nov; 28():29-34. PubMed ID: 25236390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HBV and HIV viral load but not microbial translocation or immune activation are associated with liver fibrosis among patients in South Africa.
    Maponga TG; Andersson MI; van Rensburg CJ; Arends JE; Taljaard J; Preiser W; Glashoff RH
    BMC Infect Dis; 2018 May; 18(1):214. PubMed ID: 29739341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
    Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
    J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients.
    Arendt E; Jaroszewicz J; Rockstroh J; Meyer-Olson D; Zacher BJ; Mederacke I; Manns MP; Wedemeyer H; Cornberg M; Wursthorn K
    Viral Immunol; 2012 Dec; 25(6):442-7. PubMed ID: 23131018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
    Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
    AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?
    Rana U; Driedger M; Sereda P; Pan S; Ding E; Wong A; Walmsley S; Klein M; Kelly D; Loutfy M; Thomas R; Sanche S; Kroch A; Machouf N; Roy-Gagnon MH; Hogg R; Cooper CL;
    BMC Infect Dis; 2019 Nov; 19(1):982. PubMed ID: 31752729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients.
    Otegbayo JA; Taiwo BO; Akingbola TS; Odaibo GN; Adedapo KS; Penugonda S; Adewole IF; Olaleye DO; Murphy R; Kanki P
    Ann Hepatol; 2008; 7(2):152-6. PubMed ID: 18626434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.